# EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

> **NCT03594110** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 6609 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT03594110
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-31
- **Primary completion:** 2022-07-05
- **Final completion:** 2024-07-02
- **Target enrollment:** 6609 (ACTUAL)
- **Last updated:** 2025-07-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03594110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03594110, "EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03594110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*